Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
International Journal of Stroke : Official Journal of the International Stroke Society|April 7, 2026
Infarct Growth Rate and Tenecteplase Benefit in Ischemic Stroke at 4.5 to 24 Hours Without Thrombectomy --A Secondary Analysis of the TRACE-Ⅲ Randomized TrialLiyuan Wang, Li Zhou, Jinfeng Yin, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 20, 2025
Deleterious, protein-altering variants in GSPT2 are putatively associated with an X-linked neurodevelopmental disorder with intellectual disability, language impairment, autism and epilepsyYuda Wei, Kai Liu, Changrui Mi, et al.
Cerebrovascular Diseases (Basel, Switzerland)|September 9, 2024
Efficacy and Safety of Chinese Herbal Medicine in Patients with Acute Intracerebral Hemorrhage: Protocol for a Randomized Placebo-Controlled Double-Blinded Multicenter TrialYang Zhao, Wanzhen Cui, Tingting Xie, et al.
Lancet (London, England)|May 11, 2026
Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trialAnxin Wang, Xue Xia, Ying Tang, et al.
JAMA|May 8, 2026
Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical TrialYunyun Xiong, Fengyuan Che, Hao Wang, et al.
The New England Journal of Medicine|June 17, 2024
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without ThrombectomyYunyun Xiong, Bruce C V Campbell, Lee H Schwamm, et al.
Lancet (London, England)|February 8, 2026
Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trialYunyun Xiong, Fana Alemseged, Zhixin Cao, et al.
Lancet (London, England)|November 15, 2024
Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trialJianwen Guo, Xiaoying Chen, Manli Wu, et al.
Molecular Psychiatry|November 2, 2019
Mutations in ASH1L confer susceptibility to Tourette syndromeShiguo Liu, Miaomiao Tian, Fan He, et al.
Nature Communications|December 14, 2025
Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trialHao Wang, Ho Ko, Thomas W Leung, et al.
Pageof 11